The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

The Bagsvaerd, Denmark, company said that if the application is approved, Wegovy would become the first oral formulation of a ...

Prior to starting the trial, the participants also had moderate to high levels of scar tissue in the liver, known as stage 2 ...

Novo Nordisk (NVO) announced Friday that the U.S. Food and Drug Administration (FDA) accepted its marketing application for ...

Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...

A decision is expected in the fourth quarter of 2025.

A batch of the drug is under a limited voluntary recall after a shipping error exposed certain doses to improper temperatures.

A late-stage clinical study showed that this weight loss drug helped 2 out of 3 people with the life-threatening liver ...

Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...

Wegovy to become preferred GLP-1 drug on CVS Caremark's top formularies in 2025 as Novo Nordisk expands patient access ...

Novo Nordisk said on Tuesday it was working with telehealth firms Hims & Hers , Ro and LifeMD to sell Wegovy, as it looks to ...